CLDX Celldex Therapeutics, Inc.


$ 26.80 $ 0.28 (1.05 %)    

Friday, 17-Oct-2025 15:59:30 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 26.83
$ 26.35
$ 22.65 x 20
$ 28.28 x 45
$ 26.03 - $ 27.01
$ 14.40 - $ 29.38
704,642
na
1.78B
$ 1.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-initiates-coverage-on-celldex-therapeutics-with-underweight-rating-announces-price-target-of-25

Barclays analyst Etzer Darout initiates coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Underweight rating and announc...

 canaccord-genuity-maintains-buy-on-celldex-therapeutics-maintains-62-price-target

Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $62 price target.

 wells-fargo-maintains-overweight-on-celldex-therapeutics-lowers-price-target-to-38

Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target...

 citigroup-maintains-buy-on-celldex-therapeutics-lowers-price-target-to-48

Citigroup analyst David Lebowitz maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $5...

 celldex-therapeutics-pulls-plug-on-eosinophilic-esophagitis-investigational-drug-as-data-falls-short

Celldex will stop developing barzolvolimab in eosinophilic esophagitis after Phase 2 data showed strong mast cell reduction but...

 canaccord-genuity-maintains-buy-on-celldex-therapeutics-lowers-price-target-to-62

Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target fr...

 hc-wainwright--co-maintains-buy-on-celldex-therapeutics-lowers-price-target-to-42

HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the pric...

 celldex-reports-phase-2-topline-results-for-barzolvolimab-in-eosinophilic-esophagitis-says-study-met-primary-endpoint-demonstrating-barzolvolimabs-ability-to-potently-deplete-mast-cells-in-gastrointestinal-tract

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported topline results from the Company's ongoing Phase 2 study of barzolv...

 celldex-therapeutics-13g-filing-shows-point72-asset-management-reported-a-67-stake-in-co-as-of-july-2-2025

- SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION